Eddingpharm Buys China Marketing Rights For GSK Breast-Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
China's Eddingpharm drug marketer has bought the local rights for GlaxoSmithKline's recently approved Tykerb (lapatinib) for treating metastatic breast cancer.